Regencell Bioscience Holdings Limited (RGC)
NEUTRALFondamental
66
Prix
$5.46
Capitalisation boursière
-
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$3.16B
12 derniers mois (au 31/12/2017)
Résultat net
$112M
12 derniers mois (au 31/12/2017)
Flux de trésorerie libre
-
Capitaux propres totaux
$-856M
Passif total
$3.70B
Ratio de liquidité général
0.83
Couverture des intérêts
-
Dette/EBITDA
-
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$3.74
Prix actuel
$5.46
Marge de sécurité
-45.9%
Fourchette de juste valeur
$3.55 - $3.93
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
7.35
ROE
-13.1%
Ratio P/B
-
P/FCF
-
Marge brute
-
ROIC
9.4%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
9.4%
WACC
11.6%
ROIC − WACC
-2.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (11)
- EPS shows upward trend
- EPS CAGR 18.50%
- Price CAGR 44.61%
- ROIC 9.4%
- Operating Margin 8.6%
- Current Ratio
- Return on Tangible Assets
- Low reliance on intangibles
- Earnings Quality (OCF/NI) 3.65
- Share Dilution -0.3%
- Piotroski F-Score 5/9
Échoué (3)
- DCF valuation (Unknown)
- ROE -231.9%
- Net Margin Trend 3.6% vs 5.3%
Indisponible (14)
- Gross Margin NaN%
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO | 52 |
| Ms. Michelle Chan | Financial Controller, CFO & Principal Financial Officer | - |
| Mr. Wai Hong Chung | COO, Chief Strategy Officer & Director | 47 |
| Ms. Antonia Assang | Senior Vice President of Project Management | - |
| Mr. Yat-Pui Au | Chief Business Officer | 50 |
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for RGC, sourced from Markets Gazette.
- 3/5/2026NEGATIVEDon't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag
The article warns investors against buying Regencell Bioscience stock (RGC), highlighting a critical "red flag." While the company is exploring Traditional Chinese Medicine (TCM) opportunities, the exact nature and viability of these ventures remain unclear. This lack of transparency or concrete details regarding Regencell Bioscience's TCM strategies poses a significant risk. For investors, this indicates high uncertainty and potential undisclosed issues, making the stock unsuitable for speculative investment until operational details and market potential are clarified.
- 3/1/2026NEGATIVEForget Regencell Bioscience: This Blue Chip Drug Maker Is the Boring Compounder You Need
A recent financial analysis article advises investors to disregard general market sentiment concerning Regencell Bioscience Holdings Limited. While not providing specific details, the analysis casts the company in an unfavorable light, suggesting to "forget" it in favor of an unspecified blue-chip drug maker, described as a "boring compounder" that investors need. This implies a cautious or negative outlook on Regencell, suggesting its prospects might not be as promising as market perception, or that more solid, less volatile alternatives exist. Investors should consider this as a potential red flag, prompting further due diligence on the company before making investment decisions.
via Markets Gazette